Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Prostatic Neoplasms 4 Glioblastoma 4 Carcinoma, Renal Cell 4 Sarcoma, Alveolar Soft Part 3 Sarcoma 3 Gliosarcoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uveal Melanoma 2 Uterine Cervical Neoplasms 2 Solitary Fibrous Tumor, Pleural 2 Mesothelioma, Malignant 2 Colorectal Neoplasms 2 Carcinosarcoma 2 Carcinoma, Ovarian Epithelial 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Tongue Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Pleural Effusion, Malignant 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Neoplasm Metastasis 1

Interventions

Gemcitabine 13 Doxorubicin 8 Docetaxel 7 Trabectedin 5 pazopanib 4 Nivolumab 4 Temozolomide 3 Specimen Handling 3 Sorafenib 3 rucaparib 2 pembrolizumab 2 liposomal doxorubicin 2 durvalumab 2 brostallicin 2 Sunitinib 2 Radiotherapy 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Letrozole 2 Ifosfamide 2 Dacarbazine 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 saracatinib 1 rubitecan 1 romidepsin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leiomyosarcoma × cediranib × Clear all

NCT03851614 2026-02-09

DAPPER

University Health Network, Toronto

Phase 2 Active not recruiting

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡